diabetestalk.net

Invokana Vs Januvia Cost

Jardiance Vs Invokana Vs Farxiga Side Effects, Cost, Dosage

Jardiance Vs Invokana Vs Farxiga Side Effects, Cost, Dosage

Jardiance vs Invokana vs Farxiga Side effects, Cost, Dosage Compare Jardiance vs Invokana vs Farxiga cost, side effects, and dosage. These are the new diabetes type-2 treatment drugs , approved by FDA. These oral diabetes pills get rid of glucose from the bloodstream, by excreting it into the urine. The manufacturers also claim that they cause weight loss , an influential selling point for a diabetes drug. Diabetes Mellitus is a metabolic disorder, characterized by high blood sugar level for long period of time. It is one of the most common diseases around the world. The International Diabetes Federation (IDF) reports 387 million people with diabetes, among them 90% have type 2 diabetes. Diabetes Symptoms include high blood sugar level, frequent urination with urgency, ketoacidosis, increased thirst. In severe conditions, a patient may go into the coma. Diabetes Type 2 or Diabetes mellitus type 2 is more common as compared to type 1 diabetes. The pancreas gradually loses the capacity to produce enough insulin and requires injection of insulin hormone externally. Type 2 diabetes long-term complications include retinopathy, kidney failure, cardiovascular diseases, leg ulcers, impaired healing and muscular weakness. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Before we move towards the actual Jardiance vs Invokana vs Farxiga comparison, lets clear the point that Invokana, Jardiance, and Farxiga all three are SGLT2 inhibitors drugs. Which means they share the same mechanism of action, which relies on blocking sodium glucose cotransporter-2 (SGLT2), a key protein in the kidney filtration process, to drain the sugar from blood to urine. It also implies that most of the side effects are same for all of these drugs. Lets look at their generic chemical compounds and manufa Continue reading >>

Cost-effectiveness Of Canagliflozin Versus Sitagliptin As Add-on To Metformin In Patients With Type 2 Diabetes Mellitus In Mexico

Cost-effectiveness Of Canagliflozin Versus Sitagliptin As Add-on To Metformin In Patients With Type 2 Diabetes Mellitus In Mexico

Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico Author links open overlay panel CherylNeslusanPhD1 To assess the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico. A validated model (Economic and Health Outcomes [ECHO]-T2DM) was used to estimate the cost-effectiveness of canagliflozin 300 or 100 mg versus sitagliptin 100 mg in patients with T2DM inadequately controlled on metformin monotherapy. Data from a head-to-head, phase III clinical trial, including patients baseline demographic characteristics, biomarker values, and treatment effects, were used to simulate outcomes and resource use over 20 years from the perspective of the Mexican health care system. Costs of complications and adverse events were tailored to the Mexican setting and discounted at 5%. Cost-effectiveness was assessed using willingness-to-pay thresholds equivalent to 1 times the gross domestic product per capita (locally perceived to be very cost-effective) and 3 times the gross domestic product per capita (locally perceived to be cost-effective) on the basis of recommendations of the Mexican government and the World Health Organization. Owing primarily to better glycated hemoglobin (HbA1c), body weight, and systolic blood pressure values, canagliflozin 300 and 100 mg were associated with an incremental benefit of 0.16 and 0.06 quality-adjusted life-years (QALYs) versus sitagliptin 100 mg, respectively, over 20 years. The mean differences in cost for canagliflozin 300 and 100 mg versus sitagliptin 100 mg were Mexican pesos (MXP) 1797 (US $134) and MXP 7262 (US $540), respectively, resulting in a cost per QALY gained of MXP 11, Continue reading >>

How Invokana Works: New Type 2 Diabetes Drug Hailed As A Major Treatment Advance

How Invokana Works: New Type 2 Diabetes Drug Hailed As A Major Treatment Advance

Approval of Invokana, new kind of type 2 diabetes drug, by the U.S. Food and Drug Administration means diabetics have a significant new tool for treating the disease, as well as for losing weight and improving their overall health. “It’s not hype to say that this is a new class of drug that could provide patients with a lot of beneficial results,” Dr. Zachary Bloomgarden, Clinical Professor in the Department of Medicine, Division of Endocrinology at Mount Sinai School of Medicine and a nationally renowned diabetes educator and lecturer, said about the approval of the new drug, canagliflozin, which will be sold under the brand name Invokana. “The bottom line with this drug is that it controlled blood sugar levels without causing weight gain and caused almost no hypoglycemia. This drug could be the backbone of new treatments for type 2 diabetes.” How Invokana Works In development for the last 13 years, Invokana employs a “novel mechanism of action” to lower blood sugar in type 2 diabetics, Bloomgarden says. The medication is a sodium glucose co-transporter 2 (SGLT2) inhibitor, according to the drug’s developer Janssen Pharmaceuticals, Inc., a part of Johnson & Johnson. Invokana works by inhibiting sodium glucose co-transporter 2, a carrier that aids in the reabsorption of glucose into the bloodstream through the kidneys, which occurs during the process in which blood is filtered through the kidneys. The excess glucose is then flushed out of the body, which is why Invokana also acts as a “potent diuretic,” Bloomgarden said. “One of the most basic biological factors driving the diabetes and obesity epidemics is that our bodies have evolved to never waste food and energy,” medical journalist Alasdair Wilkins said when describing how Invokana works. Continue reading >>

How To Afford Really Expensive Diabetes Medication

How To Afford Really Expensive Diabetes Medication

This Diabetes Education UPDATE focuses on a patient advocacy area called, “how to afford REALLY expensive medication” For people with type 2 diabetes, metformin and sulfonyrea like glimepiride or glyburide are cheap meds ($4 list), however, after that the diabetes medication cost skyrockets. Oral pills like Januvia or Tradjenta can be $200-300 per month, injectable meds like bydureon, tanzeum, or trulicity are $500 a month, various insulins like lantus/levemir or humalog/novolog can be $300 or more per month EACH, recently a patient’s monthly insulin bill before insurance was $2000/month, after insurance it was “only” $648/month. These meds aren’t including the price for test strips that can often be $50-200 month depending on how often they test. Oh yeah, what about lab costs? Office visits? Education? and that many people with diabetes will also have other chronic illnesses they are treating such as cholesterol, blood pressure, mental health, and etc. My focus here is to help these people get the medication they need at an affordable price, most of the time we can figure something out. As diabetes educator, I make it a point to “be in the know” with various opportunities, some insurance companies cover other meds in the same class better, people with medicaid have specific covered meds to help with cost, same with medicare, and people with commercial insurance can utilize copay cards that suddenly take a $600 med bill down to $0-25 bill, which is ALOT easier, the patient will be less stressed, the patient will be more compliant, the patient will probably be more loyal to our facility, and the patient will most likely be better controlled and healthier. I urge any of you that hear of a patient with diabetes that is struggling to pay for the meds or take Continue reading >>

Invokana Tops Januvia As Third-line Therapy, With Drawbacks

Invokana Tops Januvia As Third-line Therapy, With Drawbacks

Invokana Tops Januvia as Third-Line Therapy, With Drawbacks In a phase 3 trial of patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin (Invokana, Janssen Pharmaceuticals) improved glycemic control better than adding sitagliptin (Januvia, Merck), but genital fungal infections were a common side effect. The results, first reported in part at the American Diabetes Association meeting in 2012, have now been published online April 5 in Diabetes Care. At 52 weeks, the patients' mean glycated hemoglobin A1C (HbA1C) levels dropped by 1.03% with canagliflozin vs 0.66% with sitagliptin. Canagliflozin also resulted in weight loss and a drop in blood pressure. However, 9.2% of men and 15.3% of women developed genital infections while taking this drug. "In this specific patient population, metformin- plus sulfonylurea-treated patients, canagliflozin was the winner vs sitagliptin," lead author Guntram Schernthaner, MD, from Rudolfstiftung Hospital-Vienna, in Austria, told Medscape Medical News. "It has all 3 effects with 1 drug," he noted, adding, however, that it should not be used in patients who have impaired kidney function or those taking strong diuretics. Canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is the first drug in this class to be cleared by the US Food and Drug Administration for treating type 2 diabetes, gaining approval just last month, albeit with the caveat that 5 postmarketing studies , including a cardiovascular safety outcomes trial, CANVAS , must be conducted as a condition of approval. The drug inhibits the reabsorption of glucose from the kidneys back into the blood, leading to increased glucose in the urine and decreased glucose levels in the blood. Sitagliptin, a dipeptidyl peptidase-4 (DPP Continue reading >>

Compare Invokana Vs Januvia - Comprehensive Analysis By Treato

Compare Invokana Vs Januvia - Comprehensive Analysis By Treato

To those of you who are using things like Invokana and ... Didn't get on yesterday. I went to the doctor and then had lunch with my friend. When I cam e home I felt lousy. My knee is still very sore. The doctor said he thinks it's a sprained tendon or ligament (I for got which he said), but he X-rayed it anyway. Today I went to volunteer at the the temple, then went out to dinner with my friend. I had roasted chicken with broccoli (steamed) and squash casserole. I didn't have lunch so I ate the roll that came with it. read more... />I am doing OK with the low carb diet, but then I don't eat a lot of carbs anyway. I am using less insulin which is good. Lynn: I've been getting my suits at Walmart for a long time. I wear a pair of short over it. To those of you who are using things like Invokana and Januvia, etc. Please take the warnings about things like pancreatitis seriously. I have a friend who was in the hospital twice with pancreatitis from taking, I forgot the name, but it;t one you take once a week. I'm sorry but I'll take insulin any day. Having had pancreatitis once, I don't ever want to have it again. I had it before I was diagnosed with diabetes and five months later Boom. Barb: Most of those nutrition bars are more like candy bars than anything else. They have too much sugar and carbs. Hope everyone had a nice day. It is hot and humid here and tornado warnings. . . . . . . ." Continue reading >>

Adjusted Mean Change In A1c With Invokana® 300 Mg Vs Januvia® 100 Mg By Baseline A1c Subgroup2

Adjusted Mean Change In A1c With Invokana® 300 Mg Vs Januvia® 100 Mg By Baseline A1c Subgroup2

WARNING: LOWER-LIMB AMPUTATION An approximately 2-fold increased risk of lower-limb amputations associated with INVOKANA® use was observed in CANVAS and CANVAS-R, two large, randomized, placebo-controlled trials in patients with type 2 diabetes who had established cardiovascular disease (CVD) or were at risk for CVD. Amputations of the toe and midfoot were most frequent; however, amputations involving the leg were also observed. Some patients had multiple amputations, some involving both limbs. Before initiating, consider factors that may increase the risk of amputation, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Monitor patients receiving INVOKANA® for infection, new pain or tenderness, sores, or ulcers involving the lower limbs, and discontinue if these complications occur. CONTRAINDICATIONS History of a serious hypersensitivity reaction to INVOKANA®, such as anaphylaxis or angioedema Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis WARNINGS and PRECAUTIONS Lower-Limb Amputation: An approximately 2-fold increased risk of lower-limb amputations associated with INVOKANA® use was observed in CANVAS and CANVAS-R, two large, randomized, placebo-controlled trials evaluating patients with type 2 diabetes who had either established cardiovascular disease or were at risk for cardiovascular disease. In CANVAS, INVOKANA®-treated patients and placebo-treated patients had 5.9 and 2.8 amputations per 1000 patients per year, respectively. In CANVAS-R, INVOKANA®-treated patients and placebo-treated patients had 7.5 and 4.2 amputations per 1000 patients per year, respectively. The risk of lower-limb amputations was observed at both the 100-mg and 300-mg once-daily do Continue reading >>

Similarities And Differences Between Diabetic Drugs Invokana And Farxiga | Spanglaw

Similarities And Differences Between Diabetic Drugs Invokana And Farxiga | Spanglaw

Similarities And Differences Between Diabetic Drugs Invokana And Farxiga While Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, were the first to bring an SGLT-2 inhibitor drugInvokanato market in 2013, other companies were not far behind. AstraZeneca and Bristol Myers Squibb Company brought the SGLT-2 inhibitor drug Farxiga out in January, of 2014. Soon after came Boehringer Ingelheims Jardiance, Janssens Invokamet, AstraZenecas Xigduo XR, and Eli Lilys Glyxambi. Despite the fact that the FDA approved Invokana as well as the other five SGLT-2 drugs, the vote for Invokana was 10 to 5. There were those on the panel who had concerns regarding the safety and long-term effects of SGLT-2 inhibitors. The panel required that J & J complete an additional five studies post-market, including a cardiovascular study, a bone safety study, two pediatric studies and a program which monitored malignancies, pancreatitis, hypersensitive reactions, liver abnormalities and pregnancy outcomes. Little more than two years after the FDA approved Invokana, and even less time since the other five Type 2 diabetes drugs were approved, the agency issued a warning which stated a significant number of aftermarket reports had been received linking SGLT-2 inhibitors to ketoacidosis. Ketoacidosis is an extremely serious, potentially fatal condition in which acids build up in the bloodstream. This can happen when blood sugar levels are too high for too long a time. A body with insufficient levels of insulin will use fat for energy rather than sugar. When this fat is burned, it creates acids called ketones, and when an excess of ketones built up in the blood, the chemical balance of the blood is thrown off and the entire body is disrupted. It is rare for those with Type 2 diabetes to suffer Continue reading >>

Invokana® Is Proven To Provide Better Results Than Januvia®*

Invokana® Is Proven To Provide Better Results Than Januvia®*

INVOKANA® can cause important side effects, including: Amputations. INVOKANA® may increase your risk of lower-limb amputations. Amputations mainly involve removal of the toe or part of the foot; however, amputations involving the leg, below and above the knee, have also occurred. Some people had more than one amputation, some on both sides of the body. You may be at a higher risk of lower-limb amputation if you: have a history of amputation, have heart disease or are at risk for heart disease, have had blocked or narrowed blood vessels (usually in leg), have damage to the nerves (neuropathy) in the leg, or have had diabetic foot ulcers or sores. Call your doctor right away if you have new pain or tenderness, any sores, ulcers, or infections in your leg or foot. Your doctor may decide to stop your INVOKANA® for a while if you have any of these signs or symptoms. Talk to your doctor about proper foot care Dehydration. INVOKANA® can cause some people to become dehydrated (the loss of too much body water), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). You may be at higher risk of dehydration if you have low blood pressure, take medicines to lower your blood pressure (including diuretics [water pills]), are on a low sodium (salt) diet, have kidney problems, or are 65 years of age or older Vaginal yeast infection. Women who take INVOKANA® may get vaginal yeast infections. Symptoms include: vaginal odor, white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese), or vaginal itching Yeast infection of the penis (balanitis or balanoposthitis). Men who take INVOKANA® may get a yeast infection of the skin around the penis. Symptoms include: redness, itching, or swelling o Continue reading >>

Results From Head-to-head Studies Of Invokana (canagliflozin) Versus Januvia (sitagliptin) Highlight The Importance Of Weight-change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes

Results From Head-to-head Studies Of Invokana (canagliflozin) Versus Januvia (sitagliptin) Highlight The Importance Of Weight-change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes

Poster presented Tuesday 16th September 14:15 15:15 (Vienna Time) Note: This press release corresponds to EASD abstracts #826 and #817 Janssen-Cilag International NV (Janssen) today announced analyses based on head-to-head studies of INVOKANA (canagliflozin) versus JANUVIA (sitagliptin) as dual and triple therapy options with metformin and metformin plus sulfonylureas, respectively, amongst patients with type 2 diabetes. These data highlight the importance of weight change for weight-related quality of life (WRQoL) and physical health satisfaction (HS) and support the cost effectiveness of canagliflozin.1 These results were presented at the 50th European Association for the Study of Diabetes in Vienna, Austria ( abstract #826 and #817 ). In the analysis of the dual-therapy study, patients were categorised as continuing weight loss, prior weight loss with partial regain or no weight loss or complete regain based on trajectory of weight loss through week 52, to fully reflect the patient experience over time. Compared to patients with no weight loss or complete regain through week 52, patients with continuing weight loss were approximately twice as likely to show improvements in WRQoL (OR: 2.21, 95% CI 1.25, 3.90) and in HS (OR: 1.98, 95% CI 1.27, 3.08). Patients with prior weight loss were about 50% more likely to show improvements in HS (OR 1.56, 95% CI 1.08, 2.25). Among those who improved, a higher proportion of patients were assigned to canagliflozin treatment versus sitagliptin. In the previously reported ( ADA 2013 ) head-to-head study of canagliflozin versus sitaglitpin as dual therapy with metformin canagliflozin 100mg and 300mg was associated with a mean weight loss of 3.3kg and 3.7kg respectively, compared to a 1.2kg mean weight loss with sitagliptin, after 52 Continue reading >>

Invokana Prices And Invokana Coupons - Goodrx

Invokana Prices And Invokana Coupons - Goodrx

{"is_esrx_program_drug": false, "market_type": "on-market", "image_alt_text": "Invokana Coupon - Invokana 300mg tablet", "notices_count": 1, "canonical_link": ""dosage_slug": "300mg", "savings_tips_count": 4, "id": 37749, "sponsored_listing": null, "form_display_plural": "tablets", "common_days_supply": 30, "title": "Invokana", "dosage_form_display": "30 tablets of Invokana 300mg", "warnings": [], "dosage_form_display_short": "30 tablets 300mg", "similar_drugs": [{"display": "Abbott Freestyle", "slug": "abbott-freestyle"}, {"display": "Accu-Chek", "slug": "accu-chek"}, {"display": "Actos", "slug": "actos"}, {"display": "Amaryl", "slug": "amaryl"}, {"display": "BD Ultra-Fine", "slug": "bd-ultra-fine"}, {"display": "Bayer Contour Next", "slug": "bayer-contour-next"}, {"display": "Glucophage", "slug": "glucophage"}, {"display": "Glucophage XR", "slug": "glucophage-xr"}, {"display": "Glucotrol", "slug": "glucotrol"}, {"display": "Glucotrol XL", "slug": "glucotrol-xl"}, {"display": "Humalog", "slug": "humalog"}, {"display": "Humulin N", "slug": "humulin-n"}, {"display": "Januvia", "slug": "januvia"}, {"display": "Jardiance", "slug": "jardiance"}, {"display": "Lantus", "slug": "lantus"}, {"display": "Micronase", "slug": "micronase"}, {"display": "Novolog", "slug": "novolog"}, {"display": "Onetouch", "slug": "onetouch"}, {"display": "Trulicity", "slug": "trulicity"}, {"display": "Victoza", "slug": "victoza"}], "label": "invokana", "has_what_is": true, "equivalent_drugs": {"Invokana": {"forms": {"tablet": {"dosage_sort": ["100mg", "300mg"], "dosages": {"100mg": {"quantities": [14, 28, 30, 60, 90], "drug_id": 37748, "name": "100mg", "default_quantity": 30}, "300mg": {"quantities": [14, 15, 28, 30, 90], "drug_id": 37749, "name": "300mg", "default_quantity": 30}}, "singular": "ta Continue reading >>

Invokana Vs Metformin Comparison - Drugs.com

Invokana Vs Metformin Comparison - Drugs.com

For Diabetes, Type 2 Although this medication did bring my sugars down a bit and my tastings incredible I had to stop taking it because of constant yeast infections. I thought I could toughen it out but after being on it for three months and no sign of the infections going away my doctor took me off of it. I have also notice my hair is so much thinner and falling out. My nails were also brittle and breaking. And make sure you drink plenty of water because it dehydrates you very fast For Diabetes, Type 2 Started taking 100 mg daily at night numbers came down in a week...went to see the Doctor in a month he was happy then he prescribed 300 mg daily...soon after taking this dosage I began to experience an itching on my penis and it was driving me crazy, also experienced more frequent urination along with an insatiable thirst. I was about to schedule an appointment with my urologist until I Googled "Side effects of Invokana". The itching wouldn't stop didn't know that there were these side effects from this medication and even though it helped bring down my sugar levels I really don't think its worth the other problems it presents. I too have experienced a weight loss. It is a good medicine but the side effects aren't worth it. Sorry For Polycystic Ovary Syndrome I got my first period when I was 11 and was regular up until I was 14 and then they stopped. Fast forward to 2015 and I hadn't had a period at all for 5 years. I decided to finally do something about it, I was actually enjoying the lack of periods to be honest! I had some tests done and the diagnosis of PCOS was confirmed. My doctor put me on metformin 500mg twice a day and I hated it. I was so nauseous for the first two weeks, frequent diarrhea and lots of dizziness but it all passed. After that I began to have m Continue reading >>

5 Drugs That Are Way Cheaper In Canada

5 Drugs That Are Way Cheaper In Canada

A lot of the discussion related to curbing runaway drug prices in the United States has focused on the importation of drugs from neighboring Canada. But are drugs really less expensive there? Often, the answer is yes. For instance, here are five common medicines that are much cheaper to buy in Canada than in the United States. No. 1: EpiPen Mylan's (NASDAQ:MYL) been on the hot seat since last summer's revelation of regular price increases on the life-saving EpiPen. The treatment for severe allergic reactions has become a staple in schools, businesses, glove boxes, and purses, but its price in the United States has marched steadily higher, until recently. According to the Elsevier Gold Standard Drug Database, a pair of EpiPens cost $93.88 when Mylan acquired the drug back in 2007. Since then, EpiPen's price increased to $264.50 in 2013, $461 in 2015, and to about $600 last summer. As a result, EpiPen became a billion-dollar blockbuster medicine. Fortunately, price scrutiny resulting from reports of EpiPen's historical price increases has forced Mylan to launch a cheaper formulation and boost discounts, and that's brought the price of a two-pack down to about what it also costs in Canada. However, prior to Mylan's changes, an EpiPen two-pack cost about one-third of what it cost in the United States, or about $225. No. 2: Invokana Johnson & Johnson's (NYSE:JNJ) Invokana is a relatively new, yet top-selling, diabetes medicine used to better control insulin levels. It works by inhibiting sodium glucose co-transporter 2, which reabsorbs glucose in the kidneys. By inhibiting the ability to reabsorb glucose, Invokana allows more glucose to exit the body through urine. Currently, Invokana generates over $1 billion in global sales for J&J, the vast majority of which come from sal Continue reading >>

Invokana Compared To Metformin And Januvia

Invokana Compared To Metformin And Januvia

Every year, the American Diabetes Association updates its “standards of medical care in diabetes.” The 2016 edition, which is 119 pages long, is available here. The most important part for type 2 diabetics is found on page 61, which has a chart showing the therapies used to treat diabetes. First step is always metformin. Metformin is highly effective and low-risk, with side effects that are uncomfortable but typically not dangerous, like stomach pain, nausea, vomiting, or diarrhea. (Some patients, however, develop lactic acidosis.) When another drug is added to metformin (called “dual therapy”), there are a variety of options, including insulin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors. Invokana is a SGLT-2 inhibitor. Januvia is a DPP-4 inhibitor. SGLT-2 inhibitors like Invokana treat diabetes by acting on the kidneys, where they block the reabsorption of glucose, leading to less glucose in the blood. DPP-4 inhibitors treat diabetes by acting on the pancreas, where they help maintain higher levels of GLP-1, a hormone which triggers the production of insulin by the pancreas. As the American Diabetes Association says, “Drug choice is based on patient preferences, as well as various patient, disease, and drug characteristics, with the goal of reducing blood glucose levels while minimizing side effects, especially hypoglycemia.” Obviously, you should discuss all of these issues with your doctor, and carefully consider their advice. But when it comes to the “patient preferences,” what should you know? As the Invokana website points out, there was indeed a clinical trial where Invokana was shown to be modestly better than Januvia in reducing A1C levels. Similarly, a “retrospective matched-control coh Continue reading >>

Comparing Diabetes Drugs: Januvia Vs. Victoza

Comparing Diabetes Drugs: Januvia Vs. Victoza

blood sugar control and lost more weight than patients who took the widely prescribed oral drug Januvia, a study shows. The trial is the first to compare two classes of diabetes drugs that target insulin-regulating hormones in the gut known as incretins, researchers say. Incretin-based drugs are most often prescribed to patients who do not achieve target blood sugar levels with the drug metformin or other oral agents for diabetes. Introduced early this year, Victoza is one of two FDA-approved drugs that mimic the activity of the naturally occurring incretin hormone GLP-1. The other is the twice-daily injected drug Byetta. Januvia works by blocking DDP-4, a key enzyme that breaks down GLP-1. Both classes of drugs increase insulin secretion and decrease secretion of the hormone glucagon, which raises blood sugar. In the new study, published April 24 in TheLancet, 665 type 2 diabetes patients who failed to achieve target blood sugar levels with metformin alone were treated with either once-daily injections of Victoza, at doses of 1.2 milligrams or 1.8 milligrams, or 100 milligrams of Januvia, taken by mouth once a day. Over 26 weeks of treatment, patients on the highest dosage of the injected drug achieved the best blood sugar control and the most weight loss. A main focus of the study was how well the two drugs lowered A1c, which measures blood sugar control over time. Nearly twice as many patients taking Victoza reached a target A1c level of less than 7%, according to study researcher Richard Pratley, MD, of the University of Vermont College of Medicine. The study was funded by Victoza manufacturer Novo Nordisk, which also participated in the study design, data collection, and data analysis. Pratley also acknowledged receiving consulting fees from both Novo Nordisk and M Continue reading >>

More in diabetes